Pipeline, Portfolio, and Products
Driven by a patient-first mindset, we connect technology and life-sciences expertise to propel patient-needed therapies sooner.
** This list is comprised only of therapies/indications in the U.S. and does not reflect approvals outside the U.S.
* Products of Myovant, a publicly listed company, in which Sumitovant holds a majority ownership interest.
+ Licensed to third parties for development/commercialization in certain territories; for more details, visit the product websites provided below.
Creating innovative treatment options for people living with urologic conditions.
Advancing novel regenerative therapies for pediatric rare diseases.
Women’s health and prostate cancer.
Developing gene therapies for genetic lung diseases.
Developing therapies addressing rare respiratory diseases.
* Sumitovant holds a majority ownership interest in Myovant, a publicly listed company.
To learn more about Gemtesa, visit the following website:
To learn more about Rethymic, visit the following website:
Please use the link below to download a PDF version of the following documents: Full Prescribing Information
To learn more about Orgovyx, visit the following website: